|
US20110105995A1
(en)
*
|
2008-01-16 |
2011-05-05 |
Zhu Ting F |
Uniform-sized, multi-drug carrying, and photosensitive liposomes for advanced drug delivery
|
|
WO2011140393A1
(en)
|
2010-05-05 |
2011-11-10 |
Prolynx Llc |
Controlled release from macromolecular conjugates
|
|
EP2729179B1
(en)
|
2011-06-06 |
2020-09-23 |
Starpharma Pty Ltd |
Macromolecules
|
|
WO2013036857A1
(en)
*
|
2011-09-07 |
2013-03-14 |
Prolynx Llc |
Sulfone linkers
|
|
AU2012304337B2
(en)
|
2011-09-07 |
2015-05-07 |
Prolynx Llc |
Hydrogels with biodegradable crosslinking
|
|
EP2850201A4
(en)
*
|
2012-05-11 |
2016-08-31 |
Alexander Krantz |
Site-specific labeling and targeted administration of proteins for the treatment of cancer
|
|
EP2925256A4
(en)
*
|
2013-01-22 |
2016-08-17 |
Prolynx Llc |
SEALANTS HAVING CONTROLLED DEGRADATION
|
|
ES2966631T3
(es)
|
2013-06-19 |
2024-04-23 |
Univ California |
Estructuras químicas para el suministro localizado de agentes terapéuticos
|
|
CN106232131A
(zh)
*
|
2013-10-22 |
2016-12-14 |
普洛林克斯有限责任公司 |
生长抑素和其类似物的结合物
|
|
IL290330B2
(en)
*
|
2013-12-19 |
2023-09-01 |
Seagen Inc |
Methylene carbamate binders for use with drug-targeting conjugates
|
|
CN106659796B
(zh)
|
2014-03-14 |
2021-04-30 |
加利福尼亚大学董事会 |
Tco缀合物和治疗剂递送方法
|
|
IL259829B2
(en)
|
2016-01-08 |
2023-03-01 |
Ascendis Pharma Growth Disorders As |
Controlled-release cnp agonists with low npr–c binding
|
|
CN108472380B
(zh)
|
2016-01-08 |
2022-03-01 |
阿森迪斯药物生长障碍股份有限公司 |
具有增加的nep稳定性的控制释放cnp激动剂
|
|
WO2017118698A1
(en)
|
2016-01-08 |
2017-07-13 |
Ascendis Pharma Growth Disorders A/S |
Cnp prodrugs with carrier attachment at the ring moiety
|
|
US10835578B2
(en)
|
2016-01-08 |
2020-11-17 |
Ascendis Pharma Growth Disorders A/S |
CNP prodrugs with large carrier moieties
|
|
WO2017118703A1
(en)
|
2016-01-08 |
2017-07-13 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release cnp agonists with low initial npr-b activity
|
|
WO2017118707A1
(en)
|
2016-01-08 |
2017-07-13 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release cnp agonists with reduced side-effects
|
|
BR112018017091A2
(pt)
|
2016-03-01 |
2019-01-02 |
Ascendis Pharma Bone Diseases As |
profármacos de pth
|
|
CN109414469A
(zh)
*
|
2016-03-16 |
2019-03-01 |
普罗林科斯有限责任公司 |
艾塞那肽类似物的缓释偶联物
|
|
AU2017295938C1
(en)
|
2016-07-13 |
2021-10-07 |
Ascendis Pharma A/S |
Conjugation method for carrier-linked prodrugs
|
|
US11590207B2
(en)
|
2016-09-29 |
2023-02-28 |
Ascendis Pharma Bone Diseases A/S |
Dosage regimen for a controlled-release PTH compound
|
|
KR20230170810A
(ko)
|
2016-09-29 |
2023-12-19 |
아센디스 파마 본 디지즈 에이/에스 |
낮은 피크 대 트로프 비를 가진 pth 화합물
|
|
EP4223309A1
(en)
|
2016-09-29 |
2023-08-09 |
Ascendis Pharma Growth Disorders A/S |
Combination therapy with controlled-release cnp agonists
|
|
US12453778B2
(en)
|
2016-09-29 |
2025-10-28 |
Ascendis Pharma Bone Diseases A/S |
Incremental dose finding in controlled-release PTH compounds
|
|
JOP20190191A1
(ar)
|
2017-02-22 |
2019-08-08 |
Astrazeneca Ab |
وحدات شجرية علاجية
|
|
JP7216006B2
(ja)
|
2017-03-22 |
2023-01-31 |
ジェネンテック， インコーポレイテッド |
ヒドロゲル架橋ヒアルロン酸プロドラッグ組成物及び方法
|
|
JOP20190245A1
(ar)
|
2017-04-20 |
2019-10-15 |
Novartis Ag |
أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
|
|
US11965041B2
(en)
|
2017-09-19 |
2024-04-23 |
Technische Universitaet Muenchen |
N-methylated cyclic peptides and their prodrugs
|
|
WO2019058367A1
(en)
*
|
2017-09-19 |
2019-03-28 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
LIPOPHILIC PRODRUGS BASED ON PEPTIDES
|
|
WO2019140266A1
(en)
|
2018-01-12 |
2019-07-18 |
Prolynx Llc |
Protocol for minimizing toxicity of combination dosages and imaging agent for verification
|
|
US11213596B2
(en)
|
2018-03-12 |
2022-01-04 |
Boston Scientific Scimed, Inc. |
Radiocontrast agents, scavenging methods, and scavenging system
|
|
US20210008168A1
(en)
|
2018-03-28 |
2021-01-14 |
Ascendis Pharma A/S |
Conjugates
|
|
CA3093722A1
(en)
|
2018-03-28 |
2019-10-03 |
Ascendis Pharma Oncology Division A/S |
Il-2 conjugates
|
|
DK3793587T3
(da)
|
2018-05-18 |
2025-07-21 |
Ascendis Pharma Bone Diseases As |
Startdosis af pth-konjugater
|
|
BR112021000658A2
(pt)
|
2018-07-19 |
2021-04-13 |
Starpharma Pty Ltd |
Dendrímero, composições, composição farmacêutica, método de tratamento de câncer, uso de dendrímero, método, uso, dendrímero ou composição, processo de produção de dendrímero e intermediários para a produção de dendrímero
|
|
US12071517B2
(en)
|
2018-07-19 |
2024-08-27 |
Starpharma Pty Ltd. |
Therapeutic dendrimer
|
|
CA3114329A1
(en)
|
2018-09-26 |
2020-04-02 |
Ascendis Pharma A/S |
Novel hydrogel conjugates
|
|
US20210330798A1
(en)
|
2018-09-26 |
2021-10-28 |
Ascendis Pharma A/S |
Treatment of infections
|
|
AU2019348440B2
(en)
|
2018-09-26 |
2024-09-12 |
Ascendis Pharma A/S |
Degradable hyaluronic acid hydrogels
|
|
AR116566A1
(es)
|
2018-10-03 |
2021-05-19 |
Novartis Ag |
Administración sostenida de polipéptidos similares a la angiopoyetina 3
|
|
WO2020141222A1
(en)
|
2019-01-04 |
2020-07-09 |
Ascendis Pharma A/S |
Sustained local drug levels for innate immune agonists
|
|
AU2020205029A1
(en)
|
2019-01-04 |
2021-06-24 |
Ascendis Pharma Oncology Division A/S |
Minimization of systemic inflammation
|
|
US20220054477A1
(en)
|
2019-01-04 |
2022-02-24 |
Ascendis Pharma Oncology Division A/S |
Induction of sustained local inflammation
|
|
JP2022516308A
(ja)
|
2019-01-04 |
2022-02-25 |
アセンディス ファーマ オンコロジー ディヴィジョン エー／エス |
パターン認識受容体アゴニストのコンジュゲート
|
|
MY209748A
(en)
|
2019-02-11 |
2025-07-31 |
Ascendis Pharma Bone Diseases As |
Liquid pharmaceutical formulations of pth conjugates
|
|
MX2021008708A
(es)
|
2019-02-11 |
2021-09-21 |
Ascendis Pharma Growth Disorders As |
Formulaciones farmaceuticas secas de conjugados de peptido natriuretico tipo c (cnp).
|
|
CN114286693A
(zh)
*
|
2019-04-05 |
2022-04-05 |
普罗林科斯有限责任公司 |
改良偶联接头
|
|
JP7608360B2
(ja)
*
|
2019-04-26 |
2025-01-06 |
プロリンクス エルエルシー |
徐放性サイトカインコンジュゲート
|
|
AU2020295724A1
(en)
|
2019-06-21 |
2021-12-02 |
Ascendis Pharma Oncology Division A/S |
Tyrosine kinase inhibitor conjugates
|
|
WO2020254617A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Anti-ctla4 compounds with localized pk properties
|
|
US20220305136A1
(en)
|
2019-06-21 |
2022-09-29 |
Ascendis Pharma Oncology Division A/S |
Anti-ctla4 conjugates
|
|
WO2020254612A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
|
|
WO2020254613A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
|
|
WO2020254607A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Anti-ctla4 compounds with localized pd properties
|
|
KR20220024690A
(ko)
*
|
2019-06-21 |
2022-03-03 |
아센디스 파마 에이에스 |
π 전자쌍 공여 헤테로방향족 질소 포함 화합물의 컨쥬게이트
|
|
EP4037715A4
(en)
*
|
2019-09-30 |
2023-12-13 |
OD Therapeutics Limited |
Protein-macromolecule conjugates and methods of use thereof
|
|
IL294357A
(en)
|
2020-01-13 |
2022-08-01 |
Ascendis Pharma Bone Diseases As |
Hypoparathyroidism treatment
|
|
CA3175974A1
(en)
|
2020-05-04 |
2021-11-11 |
Oliver Boris Stauch |
Hydrogel irradiation
|
|
US12428461B2
(en)
|
2020-06-03 |
2025-09-30 |
Ascendis Pharma Oncology Division A/S |
Treating cancer with a conjugate comprising an IL-2 moiety
|
|
JP2023540701A
(ja)
|
2020-08-28 |
2023-09-26 |
アセンディス ファーマ オンコロジー ディヴィジョン エー／エス |
グリコシル化ｉｌ－２タンパク質及びその使用
|
|
US20230364199A1
(en)
|
2020-09-28 |
2023-11-16 |
Ascendis Pharma Bone Diseases A/S |
Improvement of physical and mental well-being of patients with hypoparathyroidism
|
|
EP4314035A1
(en)
|
2021-04-01 |
2024-02-07 |
Ascendis Pharma A/S |
Use of long-acting growth hormone for treating inflammation-induced diseases
|
|
AU2022350937A1
(en)
|
2021-09-22 |
2024-03-21 |
Ascendis Pharma Bone Diseases A/S |
Long-acting pth compound treatments
|
|
WO2023069510A1
(en)
*
|
2021-10-19 |
2023-04-27 |
The United States Government As Represented By The Department Of Veterans Affairs |
Cannabinoid compositions for gastroesophageal disorders
|
|
WO2023110758A1
(en)
|
2021-12-13 |
2023-06-22 |
Ascendis Pharma Growth Disorders A/S |
Effective doses of cnp conjugates
|
|
EP4448011A2
(en)
|
2021-12-13 |
2024-10-23 |
Ascendis Pharma Oncology Division A/S |
Cancer treatments with tlr7/8 agonists
|
|
JP2025522281A
(ja)
|
2022-05-23 |
2025-07-15 |
アセンディス ファーマ グロース ディスオーダーズ エー／エス |
Ｃｎｐ化合物の液体医薬製剤
|
|
CN114874624B
(zh)
*
|
2022-05-27 |
2023-04-07 |
深圳市博致远科技有限公司 |
一种导热吸波室温固化硅橡胶产品及其制备方法
|
|
JP2025537527A
(ja)
|
2022-11-02 |
2025-11-18 |
アセンディス ファーマ ボーン ディジージズ エー／エス |
２つのｐｔｈ化合物を含むｐｔｈ治療レジメン
|
|
WO2024104922A1
(en)
|
2022-11-14 |
2024-05-23 |
Ascendis Pharma Growth Disorders A/S |
Method of improving skeletal muscle function
|
|
TW202430223A
(zh)
|
2023-01-05 |
2024-08-01 |
丹麥商阿仙帝斯眼科製藥有限公司 |
用於治療眼部病症之藥物結合物
|
|
TW202434299A
(zh)
|
2023-01-05 |
2024-09-01 |
丹麥商阿仙帝斯製藥公司 |
製造水凝膠微球之方法
|
|
AU2024233842A1
(en)
|
2023-03-06 |
2025-09-04 |
Ascendis Pharma A/S |
Multi-albumin binding compounds
|
|
IL323019A
(en)
|
2023-03-06 |
2025-10-01 |
Ascendis Pharma As |
Drug compounds with an albumin-binding moiety
|
|
WO2024184352A1
(en)
|
2023-03-06 |
2024-09-12 |
Ascendis Pharma A/S |
Drug compounds comprising albumin-binding moieties
|
|
WO2024194300A1
(en)
|
2023-03-20 |
2024-09-26 |
Ascendis Pharma Growth Disorders A/S |
Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
|
|
AU2024270185A1
(en)
|
2023-05-09 |
2025-11-06 |
Ascendis Pharma Oncology Division A/S |
Novel cancer treatments with il-2 conjugates
|
|
WO2025051711A1
(en)
|
2023-09-04 |
2025-03-13 |
Ascendis Pharma Bone Diseases A/S |
Pth treatment of chronic kidney disease
|
|
WO2025208117A1
(en)
*
|
2024-03-29 |
2025-10-02 |
Maha Therapeutics, Inc. |
Cleavable ester compounds and uses thereof
|